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1. Introduction 
In Parkinson’s disease (PD) non-motor symptoms including urinary disorders have been 
recognized as important features of the disease (Emre, 2003; Hely et al., 2005; Mathias, 2002; 
Pfeiffer, 2003; Rojo et al., 2003; Senard et al., 1997; Winge et al., 2003; Lang & Obeso, 2004). In 
this chapter we will review the clinical features, the pathophysiology and the treatment of 
urinary disturbances in PD. We will also discuss recent data on the use of intradetrusorial 
botulinum A toxin injections (BoNT/A) (Giannantoni et al., 2009; Giannantoni et al., 2011).  
2. Parkinson’s disease and neurogenic bladder 
2.1 Prevalence of urinary symptoms 
Earlier studies suggested that the prevalence of urinary symptoms in patients with PD 
ranges from 38% to 71% ( Andersen 1985; Berger et al., 1987; Hald & We, 1982; Hattori et al., 
1992; Porter et al., 1971) however in a number of these studies the clinical distinction 
between PD and other parkinsonisms, including multiple-system atrophy (MSA) was not 
addressed. Furthermore, some studies were based on patients presenting to urology clinics 
with urinary symptoms. (Berger et al., 1987; Hattori et al., 1992; Pavlakis et al., 1983). More 
recent studies in PD using validated questionnaires showed that the prevalence of urinary 
symptoms varied between 27% (Araki & Kuno, 2000a) to 39% (Campos-Sousa et al., 2003) 
and using a non validated questionnaire was greater than 40% (Sakakibara et al., 2001). 
Additionally Araki and Kuno (2000a) found a correlation between urinary disturbances and 
neurological disability and between severity of urinary disturbances and stages of the 
disease (Sakakibara et al., 2001), suggesting a relationship between dopaminergic 
degeneration and voiding dysfunction (Sakakibara et al., 2001). 
2.2 Clinical features of urinary symptoms 
Nocturia is the most prevalent lower urinary tract symptom (LUTS) reported by PD 
patients (>60%) (Campos-Sousa et al., 2003). Patients complain also of urgency (33%–54%) 
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(Araki & Kuno, 2000a; Campos Sousa et al., 2003) and frequency (16%–36%) (Araki & 
Kuno, 2000a; Campos Sousa et al., 2003), and urge urinary incontinence, particularly if 
poor mobility complicates their bladder disorder (Araki & Kuno 2000a; Campos Sousa et 
al., 2003; Lemack et al., 2000). Men with PD often have a coexisting benign prostatic 
hyperplasia worsening detrusor overactivity. In female patients overactive (urgency, 
frequency, urge incontinence) and obstructive (hesitancy, poor flow, dribbling) symptoms 
may also coexist. Evidence of bladder dysfunction in genetically determined 
Parkinsonism is controversial. In one study at least three cases of PARK1 α-synuclein–
positive individuals were incontinent (Spira et al., 2001), while in another none of 17 
patients with autosomal-recessive–type juvenile PD had bladder dysfunction (Ishikawa & 
Tsuji, 1996).  
2.3 Neurogenic causes of bladder symptoms and voiding dysfunction in PD 
There are several neurogenic causes of bladder symptoms in PD. Some Authors have 
suggested that an impaired relaxation or bradykinesia of the urethral sphincter can result in 
voiding dysfunction (Christmas et al., 1988; Galloway 1983) due to bladder outflow 
obstruction and, therefore, to detrusor overactivity. Studies using cystometry, however, 
have shown that obstructive voiding patterns are not common in PD patients (Araki et al., 
2000b; Dmochowski, 1999) indicating that other mechanisms play a significant role.  
3. Normal nervous control of the micturition reflex 
Urinary storing and micturition rely on the interplay of a number of neural structures in the 
brain, spinal cord and peripheral ganglia. The complex relationship between central and 
peripheral pathways makes lower urinary tract (LUT) susceptible to a variety of neurologic 
disorders.  
3.1 The role of Central Nervous System (CNS) in the control of the micturition reflex 
The normal micturition reflex in the adult is mediated by a spino-bulbo-spinal pathway, 
which passes through relay centers in the brain. Micturition occurs in response to afferent 
signals from the lower urinary tract, and the distension of the bladder wall is considered the 
primary stimulus (de Groat et al., 1999; de Groat & Yoshimura, 2001). 
During bladder filling, once threshold tension is achieved, afferent impulses, conveyed 
mainly by the pelvic nerve, reach the CNS. Afferent neurons send information to the 
periaqueductal gray, and relay with the pontine tegmentum, where two different regions 
involved in micturition control have been described acting independently (Blok & Holstege, 
1999a, Griffiths et al., 1990). One is a dorsomedially located M-region, corresponding to 
Barrington’s nucleus or the pontine micturition center (PMC). A more laterally located L-
region may serve as a pontine urine storage center, and likely suppress bladder contraction 
by regulating the activity of the striated musculature of the bladder outlet during urine 
storage. Centers rostral to the pons control the beginning of micturition. The forebrain, 
therefore, even though not essential for the basic micturition reflex plays a role in 
determining when and where micturition should take place (Blok & Holstege, 1999b). 
Recent positron emission tomography studies gave further information on the brain 
structures involved in urine storage and voiding (Athwal et al., 2001; Blok et al., 1997; 
Matsuura et al., 2002; Nour et al., 2000).  
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3.2 Neurotransmitters mainly involved in voiding dysfunction due to Parkinson’s 
disease 
The micturition reflexes use several transmitter systems that may be targets for drugs aimed 
at control of micturition. Among these, dopamine and GABA pathways are fully involved in 
the control of micturition reflex and depletion of dopamine and GABA has been observed in 
Parkinson’s disease. 
3.2.1 Dopamine 
Central dopaminergic pathways can have both facilitatory and inhibitory effects on 
micturition by actions on D1-like (D1 or D5) and D2-like (D2, D3, or D4) dopaminergic 
receptors. Patients with PD often have neurogenic detrusor over activity and voiding 
dysfunction (Berger et al., 1987), possibly as a consequence of nigrostriatal dopamine 
depletion and failure to activate inhibitory D1-like receptors (Yoshimura et al., 1993). 
Micturition, however, can be activated via D2-like receptors involving brainstem and 
spinal cord circuits. Microinjection of dopamine into the pontine micturition center 
reduced bladder capacity and facilitated the micturition reflex in cats (de Groat et al., 
1993). Apomorphine, which stimulates both D1- and D2-like receptors, induced bladder 
overactivity in anesthetized rats (Sillén et al., 1981). In female rats, the role of dopamine 
D1 and D2 receptors in the volume induced micturition reflex, was investigated 
cystometrically (Seki et al., 2001) and the results, which are in agreement with previously 
data (de Groat & Yoshimura, 2001), suggested that D1 receptors tonically inhibit and D2 
receptors facilitate the micturition reflex. In conclusion central dopaminergic pathways 
exhibit different effects on micturition via multiple receptors at different sites in the 
central nervous system. 
3.2.2 GABA 
GABA pathways are also involved in voiding dysfunction due to Parkinson’s disease. 
GABA (γ-amino butyric acid) has been identified as an inhibitory transmitter at both spinal 
and supraspinal synapses in the mammalian CNS. At least in some species, the supraspinal 
micturition reflex pathway is under a tonic GABAergic inhibitory control (de Groat et al., 
1993, 1999). GABA functions appear to be triggered by binding of GABA to its ionotropic 
receptors, GABA-A and GABA-C, which are ligand-gated chloride channels, and its 
metabotropic receptor, GABA-B (Chebib & Johnston, 1999). Since blockade of GABA-A and 
GABA-B receptors in the spinal cord (Igawa et al., 1993; Pehrson et al., 2002) and brain 
(Maggi et al., 1987; Pehrson et al., 2002) stimulated rat micturition, an endogenous activation 
of GABA-A and GABA-B receptors may be responsible for continuous inhibition of the 
micturition reflex within the CNS. In the spinal cord, GABA-A receptors are more numerous 
than GABA-B receptors, except for the dorsal horn where GABA-B receptors predominate 
(Malcangio and Bowery, 1996; Coggeshall and Carlton, 1997). It is well known that 
stimulation of the PMC results in an immediate relaxation of the external striated sphincter 
and a contraction of the detrusor muscle of the bladder. Blok et al. (Block et al., 1997) 
demonstrated in cats a direct pathway from the PMC to the dorsal gray commissure of the 
sacral cord. It was suggested that the pathway produced relaxation of the external striated 
sphincter during micturition via GABA -mediated inhibitory modulation on the urethral 
sphincter motoneurons in the Onuf nucleus. 
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4. The pathophysiology of voiding dysfunction in Parkinson’s disease  
The hypothesis most widely accepted is that in healthy individuals basal ganglia output has 
an overall inhibitory effect on the micturition reflex. In PD animal models depletion of 
dopaminergic neurones induces overactive bladder, (Yoshimura et al., 1993, 1998, 2003) and 
D1 receptor agonists produce inhibition of the micturition reflex in a dose-dependent 
manner while D2 receptor stimulation facilitates micturition. In PD degeneration of 
dopaminergic neurons in the substantia nigra leads to detrusor hyperactivity, through an 
inability to activate the D1-mediated tonic inhibition. A parallel mechanism may be that in 
PD, the inhibitory dopaminergic neurons originating in the substantia nigra may be more 
damaged than the excitatory dopaminergic neurons originating in the VTA, thereby 
inducing urgency and frequency. 
Patients with PD and bladder symptoms have less uptake of [123I]-2ß-carbomethoxy-3 ß-(4-
iodophenyl) tropane (ß-CIT) in the striatum than patients with PD but without bladder 
dysfunction, indicating a correlation between urinary dysfunction and degeneration of the 
nigrostriatal dopaminergic cells (Sakakibara et al., 2001). Winge and colleagues (Winge et 
al., 2005) recently demonstrated that the presence of bladder symptoms correlate with the 
decrease in the total number of dopaminergic neurones in the striatum and that the 
degeneration of the caudate correlates with severity of bladder symptoms. It is also possible 
that anti-parkinsonian medications may affect bladder function, but the results on the effects 
of levodopa or apomorphine are controversial. In one study, detrusor overactivity improved 
after administration of apomorphine and, to a lesser extent, after levodopa (Aranda & 
Cramer, 1993), but in patients showing on–off phenomena, detrusor overactivity improved 
with levodopa in some patients and worsened in others (Fitzmaurice et al., 1985). A recent 
study suggested that in advanced PD, levodopa exacerbates detrusor overactivity in the 
filling phase, but also improves bladder emptying through increased detrusor contractility 
(Uchiyama et al., 2003). The unpredictable effect of medication is not related to stage of 
disease, age, or whether the patient had symptoms of bladder dysfunction (Winge et al., 
2002). In the study of Winge and colleagues (Winge et al., 2004), the authors suggested that 
the effects of medication are mediated through cortical mechanisms, as the ability to 
separate and integrate sensory input measured using urodynamics is influenced by 
medication. 
5. Management of urinary symptoms in Parkinson’s Disease 
Questionnaires including “bother” scores identify LUTS in PD with higher specificity than 
questionnaires without “bother” scores (Winge et al., 2003). When addressing bladder 
problems in patients with Parkinsonism in daily clinical work, systematic interview is 
needed. Addressing nocturia, urgency, frequency feeling of incomplete emptying and (urge) 
incontinence often provides the needed information for initiating treatment. It is important 
to address how these symptoms affect the daily life of the patients, as symptoms of 
overactive bladder may be particularly unpleasant in a patient with an akinetic rigid 
syndrome with postural instability. 
Neurogenic bladder symptoms are generally treated with anticholinergics (Andersson, 2000; 
Appell, 1997) including oxybutynin chloride, tolterodine tartrate, and trospium chloride and 
possibly also solifenacin. No placebo control double-blind or randomized studies, however, 
have been performed in PD. Anticholinergics can be used in PD patients with urgency and 
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frequency since they reduce the parasympathetic effect on the bladder. Patients generally 
tolerate anticholinergic drugs and benefit from their use. A study in patients without 
neurological diseases showed that the extended release tolterodine produces less side effects 
than oxybutinin (Sussman & Garely, 2002; Todorova et al., 2001). Anticholinergics usually 
provide only modest clinical improvement and in more than 60% of treated patients they 
induce adverse effects such as dry mouth and constipation (Di Stasi, 2001; Winge & Fowler, 
2006). Another disadvantage is that anticholinergics may induce or worsen cognitive 
impairment (Kay & Ebinger, 2008; Winge & Fowler, 2006). There are no studies, however, 
addressing the issue of possible worsening of cognitive impairment using anticholinergics 
in patients with PD. 
6. Botulinum A toxin as second line treatment for refractory detrusor over 
activity and over active bladder symptoms 
To date when urinary incontinence persists and patients become severely disabled a long-
term indwelling catheter remains the only option for avoiding urinary incontinence. 
Botulinum A toxin has been successfully introduced for the treatment of intractable detrusor 
overactivity (Schurch et al., 2000) and it is now widely used for a number of neurological 
conditions characterized by muscle hyperactivity (Jankovic, 2004; Ward et al., 2006). 
Intravesical injections of BoNT/A provide satisfactory long-term results, and are now 
considered as second line-therapy in neurogenic patients who do not respond to standard 
anticholinergics. The use of botulinum neurotoxins in the lower urinary tract (LUT) was 
pioneered as early as 20 yr ago with injections into the urethral sphincter (Dykstra et al., 
1988) reducing bladder-voiding pressures, urethral pressures, and post void residual (PVR) 
urine.  
BoNT/A consists of a light chain attached to a heavy chain via a disulfide bond with an 
associated zinc atom. It is synthesised as a single-chain polypeptide with a molecular weight 
of 150 kDa, which is then cleft into its active dichain polypeptide form. The heavy chain 
(about 100 kDa) allows for binding to the neuron and internalisation of the toxin, whereas 
the light chain (about 50 kDa) actively cleaves SNAP25 (synaptosomal-associated protein 
with a molecular weight 25 kDa) on the protein complex that is responsible for docking and 
releasing vesicles containing neurotransmitters (Dolly, 2003).  
In neurogenic detrusor overactivity as well as in patients with idiopathic detrusor 
overactivity, the post-treatment reduction in detrusor pressures during both phasic 
involuntary contractions and on voiding (Popat et al., 2005; Reitz et al., 2004; Schurch et al., 
2005) suggests an effect of BoNT/A on the motor innervation of the detrusor, although the 
neurological deficit which additionally affects voiding efficiency in the NDO group may 
partly explain the high rate of posttreatment clean intermittent self-catheterisations (CISC). 
Patients, however, also report a rapid reduction in their sensations of urgency, which are 
associated with involuntary detrusor overactivity (Rapp et al., 2004; Schmid et al., 2006). 
Although the exact nature and cause of urgency remains to be elucidated, abnormal afferent 
activity is thought to be a significant cause of spinal NDO (Yoshimura, 1999), and much less 
is known about the role of afferents in IDO. In both neural and bladder tissue, BoNT/A 
affected the release of numerous sensory transmitters other than ACh, including adenosine 
triphosphate (ATP), substance P, calcitonin gene related peptide (CGRP), and glutamate. 
BoNT/A may also interfere with vesicle trafficking (Apostolidis et al., 2006), expression of 
sensory receptors (Apostolidis et al., 2005) and nerve growth factor (NGF) in the bladder 
www.intechopen.com
 
Towards New Therapies for Parkinson's Disease 44
wall (Giannantoni et al., 2006). It is therefore likely that in addition to a direct effect on 
detrusor motor innervation, BoNT/A also modulates intrinsic bladder reflexes through a 
multimodal effect on sensory pathways.  
In neurogenic patients it has been demonstrated that BoNT/A decrease symptoms of 
neurogenic detrusor overactivity. The majority of treated patients had spinal neurogenic 
detrusor overactivity due to spinal cord injury or multiple sclerosis. Despite heterogeneous 
designs, almost all single-injection published studies showed significant improvements in 
outcomes measures including frequency of incontinence episodes, maximum cystometric 
capacity and maximum detrusor pressure. In spinal NDO patients the mean percentage of 
those who became fully continent was 56.6% (range: 30–87%) whereas the rate of full return 
to continence was only 8% in patients with NDO due to cerebrovascular accident. After a 
rapid onset of effect (Kalsi et al., 2008), the mean duration of efficacy in single-injection 
studies was 8 months (range: 12–36 wk). Repeated treatments showed sustained clinical 
benefits in open-label studies using up to five injections of Botox or seven injections of 
Dysport (Del Popolo et al., 2008; Grosse et al., 2005; Karsenty et al., 2006, Reitz et al., 2007). 
7. Botulinum A toxin in the treatment of refractory detrusor overactivity and 
overactive bladder symptoms due to Parkinson’s disease  
Since 2000 we have been using BoNT/A as second line therapy for refractory overactive 
bladder symptoms and detrusor overactivity (DO) of both neurogenic and non-neurogenic 
origin. Here we review the results of our open label, prospective, non randomized study on 
the use of BoNT/A in patients with Parkinson’s disease affected by intractable overactive 
bladder (OAB) symptoms and DO (Giannantoni et al., 2009, Giannatoni et al., 2011). 
7.1 Patients and methods 
Seventeen patients diagnosed with PD according to United Kingdom Brain Bank criteria 
and affected by overactive bladder symptoms and DO were enrolled in a prospective study. 
They were all refractory to standard anticholinergic therapy. Disease severity was assessed 
with the Unified Parkinson’s Disease Rating Scale and Hoehn-Yahr stages 1 to 5. All patients 
had moderate-severe disability. Patients were studied while they were on their usual drug 
regimens for PD. Exclusion criteria were urogenital prolapsed in females, bladder outlet 
obstruction due to benign prostatic hyperplasia in men and recurrent urinary tract 
infections. No patients were on anticoagulant therapy or drugs interfering with 
neuromuscular transmission. The study was approved by the local ethics committee and 
patients provided informed consent. Patients unwilling or unable to perform intermittent 
catheterization, were excluded from the study. We used 150 ml as a cutoff residual volume 
for starting intermittent bladder catheterization.  
7.2 Preliminary urological assessment 
History, physical examination, serum laboratory tests, urinalysis, urine culture and urinary 
tract imaging by ultrasound were performed before commencing the study. The daily 
frequency of urinary symptoms was assessed with a voiding diary that patients completed 
for 30 days before the study. Patients were also asked to complete a standardized QoL 
questionnaire on urinary incontinence (I-QoL). Patients underwent urodynamics, including 
pressure flow studies and the recording of the electromyographic activity of pelvic floor 
muscle and external urethral sphincter, according to International Continence Society 
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Standards. During cystometry first volume and maximum pressure of uninhibited detrusor 
contractions (UDC) and maximum cystometric capacity were recorded. On pressure flow 
study detrusor pressure at maximum flow rate (pDetQmax), maximum flow rate (Qmax) 
and postvoid residual volume were monitored. All patients received a single treatment with 
BoNT/A (Botox, Allergan, Irvine-CA, USA) diluted in normal saline injected into the 
detrusor muscle. The trigone, the posterior and lateral walls of the bladder have been 
injected during cystoscopy, under short lasting general anaesthesia. Six out of the seventeen 
patients received 200 UI of BoNT/A, whereas eleven of the seventeen PD patients received 
100 UI of BoNT/A. Primary outcome measures were: changes in day-time and night-time 
urinary frequency and frequency of daily urinary incontinence episodes and in I-QoL 
questionnaire; secondary outcomes were changes on the impact of urinary symptoms in 
daily life activities was evaluated with VAS scores and in urodynamic parameters. Clinical, 
urodynamic and I-QoL and VAS were performed before, one, three and six months after 
BoNT/A injection. Urinalysis and culture were performed also at the same time intervals.  
7.3 Statistical analysis  
Friedman's repeated measures ANOVA was used to evaluate changes in the clinical scores 
and urodynamic findings of PD patients. Wilcoxon’s test was performed for the post-hoc 
analysis. Pearson's correlation coefficient was also applied and Holm's correction for 
multiple comparisons was used to disclose false significance. P<0.05 was considered to 
indicate statistical significance.  
7.4 Clinical results 
Before treatment all seventeen patients complained of increased daytime (9.29±0.3 
episodes/day) and night-time urinary frequency (4.11±0.6 episodes/night) and daily 
episodes of urinary incontinence (5.05±0.2 episodes/day). They also had urgency and low I-
QoL scores (22.8±2) and VAS scores (3.3±0.1). After BoNT/A treatment daytime and night-
time urinary frequency and the number of daily episodes of urinary incontinence were 
significantly reduced (daytime urinary frequency: p<0.0001; night-time urinary frequency: 
p=0.002; daily urinary incontinence episodes: p=0.001) (Fig.1) at one, three and six months 
follow up. Six out seventeen patients achieved a complete urinary continence at one and 3-
mos follow up. After BoNT/A treatment there was also a significant improvement in the I-
QoL and VAS scores after BoNT/A (I-QoL: p<0.0001; VAS: p<0.0002) at one, three and six 
months. Finally, we did not find any significant difference between the improvement 
observed in daytime and night-time urinary frequency, in the number of episodes of daily 
urinary incontinence and in the I-QoL and VAS scores in PD patients who received 100 UI 
with that obtained in patients treated with 200 UI of BoNT/A (p>0.05). Clinical results are 
showed in Fig.1. 
7.5 Urodynamic results 
Baseline: all the patients showed detrusor overactivity; mean values of UDC-first volume 
UDC-p max and maximum cystometric capacity were 219±20ml, 30±2cmH20 and 265±16ml, 
respectively. On pressure-flow studies, mean values of pDetQmax and Qmax were 22.3±2 
cmH2O and 18.3±1.5ml/sec, respectively. All patients completely emptied their bladders.  
After BoNT/A treatment, we observed a significant decrease in the first volume and the 
maximum pressure of uninhibited detrusor contractions and a significant increase in 
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maximum cystometric capacity at one, three and six months after treatment. Changes in 
these parameters were similar in both groups of PD patients (Fig.2). With regards to post-
void residual volume, it was similar in PD patients receiving 100 and 200 UI of BoNT/A at 
one month, whereas it returned to baseline values only in PD patients receiving 100 UI at 
three and six months after BoNT/A injection. Overall, three patients needed to perform 
intermittent catheterization twice daily for 3 months due to a high increase in post void 
residual volume after BoNT/A injection. 
 
 
Fig. 1. Daytime urinary frequency (upper panel) and night-time urinary frequency (lower 
panel) in patients with Parkinson's disease at baseline, one, three and six months after 
BoNT/A injection. Open bars represent mean data ±SE in patients injected with 200 units, 
closed bars data in patients injected with 100 units. Asterisks indicate statistical significance  
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Fig. 2. Maximum cystometric capacity and post-void residual volume in patients with 
Parkinson's disease at baseline, one, three and six months after BoNT/A injection. Each bar 
represents mean data ±SE in patients injected with 200 units and 100 units. Asterisks 
indicate statistical significance.  
7.6 Correlations between clinical and urodynamic variables 
Changes in the I-QoL significantly correlated with daytime urinary frequency (r=-0.69, 
p=0.002) in all the PD patients.  
7.7 Discussion 
In our PD patients, BoNT/A intradetrusorial injection induced a significant reduction in 
daytime and night-time urinary frequency and in the frequency of urinary incontinence, an 
increase in the quality of life scores and a significant amelioration in urodynamic 
parameters. The follow-up assessment extends our previous findings at three months 
(Giannantoni et al., 2009) by showing that the BoNT/A-induced clinical and urodynamic 
improvement lasts at least six months (Giannantoni et al., 2011). We also noted that clinical 
and urodynamic amelioration was similar when comparing patients treated with 100 UI of 
BoNT/A with those treated with 200 UI. Worth of noting, incomplete voiding symptoms 
were unrelated to the BoNT/A dosage used. Also patients with multiple sclerosis treated 
with 100 Units and patients with idiopathic overactive bladder treated with 200 and 300 
units of BoNT/A showed an increase in post-void residual volume (Flynn et al., 2009; 
Mehnert et al., 2010; Sahai et al., 2009). Our results on post-void residual volume are in 
contrast with those reported by Kulaksizoglu and Parman (Kulaksizoglu & Parman, 2010) 
who treated parkinsonian patients with Dysport 500 Units. In their series none of the 
patients studied needed intermittent catheterization. Despite of the presence of post-void 
residual volume in our PD patients, we did not observe a significant reduction in other 
parameters accounting for detrusor muscle strength (PdetQmax, Qmax). It is well known 
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that BoNT/A induces striated muscle denervation and weakness lasting about 3-4 months 
(Hamjian et al., 1994; Schiavo et al., 1994). In striated muscle it has been observed that the 
neurotoxin not only modulates extra-fusal component but also influences the altered muscle 
spindle afferent input (Abbruzzese et al., 2006; Currà & Berardelli, 2009; Rosales & Dressler, 
2010; Trompetto et al., 2008). In detrusor smooth muscle the effects of BoNT/A injection last 
longer than in striated muscle. In vitro and in vivo experimental studies suggest that the 
long-lasting effect of the BoNT/A injection in the detrusor muscle could be attributed to the 
lack of axonal sprouting, as observed in detrusor biopsies after toxin injection (Haferkamp 
et al., 2004). Studies on biopsies from patients with neurogenic overactive bladder who 
receive an intradetrusor BoNT/A injection (Apostolidis et al., 2006; Giannantoni et al., 2006), 
however, have shown decreased levels of sensory receptors P2X3, TRPV1 and NGF, thereby 
suggesting that BoNT/A may act by reducing the afferent nervous transmission.  
7.8 Conclusions 
PD patients with OAB symptoms and detrusor overactivity refractory to standard 
treatments can be successfully treated with intravesical injections of BoNT/A. Low doses 
(100 U BoNT/A) induces similar clinical and urodynamic efficacy as higher doses of the 
neurotoxin. The reported increase in post void residual volume is present only in some 
patients and lasts for a limited time. Low doses of BoNT/A can be used as second-line 
treatment for OAB symptoms and DO also in patients with PD.  
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